Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease - Wikidata - wikimedia - TriplyDB

Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease

Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease

http://www.wikidata.org/entity/Q37438625

about

Adverse safety events in patients with Chronic Kidney Disease (CKD).Neurological complications in chronic kidney disease patients.Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.American Society of Nephrology Quiz and Questionnaire 2014: RRT.The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies.

P2860

Q30245199-DDB21D34-813C-4195-992D-6BE1C5F72DB6 Q30252095-A125F093-1D75-485C-AF57-4D63B8EAFB81 Q30456721-BF2DA452-B61D-4150-B742-F40D293564EB Q35682147-1489D107-EF1E-4A26-8E05-DFDD7AEB60CE Q36072666-3FBE87FA-B19F-4AA1-97E2-80CD15B3F295 Q36198635-02F2F9D2-9666-46F5-B5DB-EEC02B0F78AB Q36423854-A8D4E9D2-3F0F-4AC2-A8D3-375A4BFF5ACB Q36801561-BDE945DC-5983-46F4-9161-63012ACB1E82 Q38037120-3678A967-F0E2-4108-897A-FD0AFFD7CB21 Q38257399-1BE1331B-6126-4165-83C4-F088BE180259 Q38281535-1C1F5385-B5D1-4B8B-A522-35ABBDA19FC2 Q38740871-F7902C62-9ABA-4A65-AA54-F793A3F7D099 Q38826645-B7A2B528-97DC-4430-89B7-CB3F52E8805A Q48252737-76625D94-2350-4C7A-9438-1C094AB009D8

P2860

Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease

http://www.wikidata.org/entity/Q37438625

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Erythropoiesis-stimulating age ...... ts with chronic kidney disease

@en

Erythropoiesis-stimulating age ...... s with chronic kidney disease.

@nl

type

label

Erythropoiesis-stimulating age ...... ts with chronic kidney disease

@en

Erythropoiesis-stimulating age ...... s with chronic kidney disease.

@nl

prefLabel

Erythropoiesis-stimulating age ...... ts with chronic kidney disease

@en

Erythropoiesis-stimulating age ...... s with chronic kidney disease.

@nl

P1433

Q37438625-FDBF0F89-F769-4EF5-9EE3-86310339106F

P1476

Q37438625-7F69AA1E-045C-47D7-A84D-49315D267454

P2093

Q37438625-1D5C4D6A-2EA2-49A5-B2F6-501F3247F43C

Q37438625-5B87A285-9407-447D-8E97-FB0E82634221

Q37438625-71E61363-82F7-49C6-9622-B4CA6E8508ED

Q37438625-7EA2ACF5-8A3E-43CD-A303-4B955DFB36A1

Q37438625-8CEFFF92-C960-4BD0-B5FB-1B4DE7F55576

Q37438625-933EFADC-EAF3-48E2-99A2-4D88DCF002C1

Q37438625-E8421800-132E-4C05-8EE7-83E9605B31A8

P2860

Q37438625-18DB3F78-FB8F-40E0-A43F-95955F76B24A

Q37438625-32DAA9C6-A8CD-4EDE-A257-0DD489E664FD

Q37438625-42BAB44E-5DB4-4685-BE53-A1AEB85F916B

Q37438625-578DEA46-A2D1-4FB9-B3FE-499C785EC23B

Q37438625-5AB19AA3-90B0-4C02-A6FB-E9815DE604A3

Q37438625-5FFECC2A-15CB-4FCD-A55F-32E7657F22BC

Q37438625-7EE66519-35AD-4575-9687-93FF1C046389

Q37438625-9E0F2F44-C7B9-476D-941C-049B162660D6

Q37438625-A3E45D5D-FD2E-44B0-B7B7-DCD07EE3FB59

Q37438625-ABC99F60-26C0-4589-9181-F885D458B8A7

P2888

Q37438625-3DCE318B-4FC9-4DC7-B0A2-45B9BAED36F5

P304

Q37438625-68696244-B7E4-40CF-8AB8-B0CC7B6DD4F9

P31

Q37438625-23E94841-C7EB-472B-BF1D-6A90C9855A99

P356

Q37438625-AB32C296-8E26-40FD-B0A9-E02B0AA77341

P407

Q37438625-C4C93709-B76B-4F49-B6A9-E9F0FE990DEB

P433

Q37438625-7F022A07-BE4C-4611-9F8F-CB705DA79249

P478

Q37438625-E7F38249-387D-4D03-AB77-D21FDBC5D3B8

P50

Q37438625-0E663E18-010B-4C0A-8ACC-9E8CFC67C956

P577

Q37438625-6FB66BBF-DE81-4C48-AFCA-75942C55A532

P5875

Q37438625-5DD43641-0F2E-4310-A94A-71255979A1BE

P698

Q37438625-CDB9945E-B8C5-4D2E-9E95-3F00E5237168

P932

Q37438625-8E66826B-5EED-420E-9D2A-52195CF292FA

P356

P1433

Kidney International

P1476

Erythropoiesis-stimulating age ...... ts with chronic kidney disease

@en

P2093

Afshin Parsa

http://www.w3.org/2001/XMLSchema#string

Amy D Zhang

http://www.w3.org/2001/XMLSchema#string

Clarissa J Diamantidis

http://www.w3.org/2001/XMLSchema#string

Loreen Walker

http://www.w3.org/2001/XMLSchema#string

Matthew R Weir

http://www.w3.org/2001/XMLSchema#string

Stephen L Seliger

http://www.w3.org/2001/XMLSchema#string

Van Doren Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Validating administrative data in stroke research.

Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Stroke and cancer: a review.

Reassessments of ESAs for cancer treatment in the US and Europe.

Anemia and health-related quality of life in adolescents with chronic kidney disease.

P2888

P304

288-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2011.49

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey C. Fink

P577

2011-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50351992

http://www.w3.org/2001/XMLSchema#string

P698

21389972

http://www.w3.org/2001/XMLSchema#string

P932

3882072

http://www.w3.org/2001/XMLSchema#string